vs

Side-by-side financial comparison of AMERICAN REBEL HOLDINGS INC (AREB) and Citius Pharmaceuticals, Inc. (CTXR). Click either name above to swap in a different company.

Citius Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.3M, roughly 1.7× AMERICAN REBEL HOLDINGS INC). Citius Pharmaceuticals, Inc. runs the higher net margin — -238.2% vs -257.5%, a 19.3% gap on every dollar of revenue.

Rebel Foods is an Indian online restaurant company which operates 11 cloud kitchen brands including Faasos, Behrouz Biryani and Oven Story. It is the largest cloud kitchen restaurant chain in the world, operating more than 450 cloud kitchens in 10 countries, as of April 2022.

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.

AREB vs CTXR — Head-to-Head

Bigger by revenue
CTXR
CTXR
1.7× larger
CTXR
$3.9M
$2.3M
AREB
Higher net margin
CTXR
CTXR
19.3% more per $
CTXR
-238.2%
-257.5%
AREB

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AREB
AREB
CTXR
CTXR
Revenue
$2.3M
$3.9M
Net Profit
$-5.9M
$-9.4M
Gross Margin
-11.2%
80.0%
Operating Margin
-171.0%
-228.7%
Net Margin
-257.5%
-238.2%
Revenue YoY
28.5%
Net Profit YoY
25.4%
8.6%
EPS (diluted)
$-63152.93
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AREB
AREB
CTXR
CTXR
Q4 25
$2.3M
$3.9M
Q3 25
$1.9M
Q2 25
$2.8M
Q1 25
$2.5M
Q4 24
$1.8M
Q3 24
$2.3M
Q2 24
$3.3M
Q1 24
$4.0M
Net Profit
AREB
AREB
CTXR
CTXR
Q4 25
$-5.9M
$-9.4M
Q3 25
$-5.2M
Q2 25
$-18.1M
Q1 25
$-5.1M
Q4 24
$-7.9M
Q3 24
$-1.7M
Q2 24
$-5.3M
Q1 24
$-2.7M
Gross Margin
AREB
AREB
CTXR
CTXR
Q4 25
-11.2%
80.0%
Q3 25
-10.5%
Q2 25
-1.1%
Q1 25
11.5%
Q4 24
-27.7%
Q3 24
-21.3%
Q2 24
0.9%
Q1 24
20.8%
Operating Margin
AREB
AREB
CTXR
CTXR
Q4 25
-171.0%
-228.7%
Q3 25
-196.0%
Q2 25
-147.7%
Q1 25
-118.1%
Q4 24
-277.8%
Q3 24
-44.5%
Q2 24
-121.3%
Q1 24
-56.3%
Net Margin
AREB
AREB
CTXR
CTXR
Q4 25
-257.5%
-238.2%
Q3 25
-278.6%
Q2 25
-638.1%
Q1 25
-201.5%
Q4 24
-443.1%
Q3 24
-74.8%
Q2 24
-161.4%
Q1 24
-66.8%
EPS (diluted)
AREB
AREB
CTXR
CTXR
Q4 25
$-63152.93
$-0.38
Q3 25
$-32.44
Q2 25
$-5.34
Q1 25
$-23.45
Q4 24
$-12273143.74
Q3 24
$-3032.24
Q2 24
$-201.01
Q1 24
$-27.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AREB
AREB
CTXR
CTXR
Cash + ST InvestmentsLiquidity on hand
$147.6K
$7.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$4.4M
$80.0M
Total Assets
$31.8M
$140.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AREB
AREB
CTXR
CTXR
Q4 25
$147.6K
$7.7M
Q3 25
$722.2K
Q2 25
$457.2K
Q1 25
$340.7K
Q4 24
$287.5K
Q3 24
$127.7K
Q2 24
$452.8K
Q1 24
$674.9K
Stockholders' Equity
AREB
AREB
CTXR
CTXR
Q4 25
$4.4M
$80.0M
Q3 25
$3.4M
Q2 25
$-3.1M
Q1 25
$-8.0M
Q4 24
$-7.6M
Q3 24
$-3.8M
Q2 24
$-1.5M
Q1 24
$2.5M
Total Assets
AREB
AREB
CTXR
CTXR
Q4 25
$31.8M
$140.4M
Q3 25
$31.7M
Q2 25
$15.0M
Q1 25
$9.7M
Q4 24
$10.0M
Q3 24
$8.9M
Q2 24
$13.2M
Q1 24
$14.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AREB
AREB
CTXR
CTXR
Operating Cash FlowLast quarter
$-2.3M
$-13.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AREB
AREB
CTXR
CTXR
Q4 25
$-2.3M
$-13.0M
Q3 25
$-1.6M
Q2 25
$-2.8M
Q1 25
$-546.5K
Q4 24
$-1.9M
Q3 24
$-1.4M
Q2 24
$-1.8M
Q1 24
$-1.9M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons